Authors : Dr. Rita D; Dr. Nisha M.S

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/2zx2mamm

Scribd : https://tinyurl.com/2ee3rpk9

DOI : https://doi.org/10.38124/ijisrt/25aug450

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Introduction: Anaemia affects 35.5% of the pregnant women globally (WHO, 2023), where the prevalence is notably higher in low and middle income countries. 1 In India, 52.2% of pregnant women are anaemic (NFHS-5), with iron deficiency causing over 60% of cases and contributing to complications like PPH, preeclampsia, sepsis, and up to 40% of maternal deaths.2Oral Iron (Ferrous sulphate/fumarate) are the First-line treatment for mild to moderate anaemia because it is Cheap, widely available but limited by Gastrointestinal side effects such as Nausea, constipation, metallic taste, Poor compliance due to intolerance.3 Intravenous Iron sucrose is indicated when oral iron is not tolerated due to GI side effects. IV Iron sucrose is a water-soluble iron (III)-hydroxide complex allowing slow, safe iron release without a test dose. IV Iron Sucrose is safer with fewer hypersensitivity reactions. It is proven to raise haemoglobin and ferritin faster than oral iron; improves iron stores and fatigue.3  Aims and objectives: To compare hemoglobin improvement between IV iron sucrose and oral ferrous fumarate in moderately to severely anemic pregnant women. To assess adverse effects, patient compliance, and satisfaction associated with each treatment  Methods: This is a prospective comparative study which is conducted at Navodaya Medical College Hospital & Research Centre, Raichur, enrolling 100 antenatal women aged 18–35 years with moderate to severe iron-deficiency anemia (Hb 7.0–10.0 g/dL) between 14–28 weeks of gestation. Participants were allocated into two groups:  Group I (n=50) received IV iron sucrose, administered on alternate days, with total dose calculated using the standard formula.  Group II (n=50) received oral ferrous fumarate (100 mg elemental iron) twice daily for four weeks. Baseline and follow-up hematological parameters (hemoglobin, ferritin, serum iron, TIBC, and hematocrit) were measured at 0, 2, and 4 weeks. Adverse effects, patient compliance, and maternal and neonatal outcomes were also recorded  Results: Both groups showed significant improvement in hemoglobin and iron indices, but the group I demonstrated superior outcomes: Hemoglobin levels at 4 weeks: Group I showed an rise in haemoglobin value by 2.1 g/dL vs Group II showed an rise in hemoglobin by 1.1 g/dL which showed statistical significance (p<0.001). Serum ferritin increased by 221.8% in the Group I versus 96.4% in the Group II which is statistically significant (p < 0.001). Adverse events were more frequent in the Group I (e.g., nausea, constipation), while the Group II had minimal side effects (e.g., mild staining, myalgia).  Conclusion: Intravenous iron sucrose is significantly more effective than oral ferrous fumarate in improving hemoglobin levels, replenishing iron stores, and achieving better maternal and neonatal outcomes in pregnant women with moderate to severe anemia. It also has a better tolerability profile. IV iron therapy should be considered the preferred modality in cases where rapid correction of anemia is necessary or when oral iron is poorly tolerated, particularly in resource-limited antenatal settings.

Keywords : Iron Deficiency Anemia; Intravenous Iron Sucrose; Oral Ferrous Fumarate.

References :

1. The global prevalence of anaemia in 2023 [Internet]. [cited 2025 May 24]. Available from: https://www.who.int/publications/i/item/9789241564960
2. IIPS/India II for PS-, ICF. India National Family Health Survey NFHS-4 2019-2021 [cited 2025 May 24]; Available from: https://dhsprogram.com/publications/publication-fr339-dhs-final-reports.cfm
3. Toteja GS, Singh P, Dhillon BS, Saxena BN, Ahmed FU, Singh RP, et al. Prevalence of anemia among pregnant women and adolescent girls in 16 districts of India. Food Nutr Bull. 2006;27:311–5.
4. Kalaivani K. Prevalence & consequences of anaemia in pregnancy. Indian J Med Res. 2009;130:627–33.
5. Tandon R, Jain A, Malhotra P. Management of Iron Deficiency Anemia in Pregnancy in India. Indian J Hematol Blood Transfus. 2018;34:204–15.
6. Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis. PLOS ONE. 2015;10:e0117383.
7. Bayoumeu F, Subiran-Buisset C, Baka N-E, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol. 2002;186:518–22.
8. al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996;69:121–4.
9. Gupta A, Manaktala U, Rathore AM. A Randomised Controlled Trial to Compare Intravenous Iron Sucrose and Oral Iron in Treatment of Iron Deficiency Anemia in Pregnancy. Indian J Hematol Blood Transfus. 2014;30:120–5.
10. V.V.N Goutham “Iron Deficiency Anaemia in Pregnancy Intravenous versus Oral route”IOSR Journal of dental and medical sciences(IOSR-JDMS), Vol.18,no.05,2019,pp01-04
11. Tonge G, Dasila PS, Pote T. Oral versus intravenous iron therapy among pregnant women with iron deficiency anaemia: a comparative study. Int J Reprod Contracept Obstet Gynecol. 2023;12(5):1384–1389. doi:10.18203/2320‑1770.ijrcog20231229.
12. Anjum S, Saini V, Saini V. Comparative study to evaluate intravenous iron sucrose with oral ferrous sulphate for treatment of anaemia in pregnancy. Int J Reprod Contracept Obstet Gynecol. 2020;9(5):1976–1980. doi:10.18203/2320‑1770.ijrcog20243171
13. Soni S, Sheetal Y, Sharma R, Kundal S, Kaur K. Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate anaemia in India. Int J Reprod Contracept Obstet Gynecol. 2023;12(9):2735–2740. doi:10.18203/2320‑1770.ijrcog20232730
14. Thobbi VA, Bijapur ZNM. A comparative study of efficacy, safety and compliance of oral iron versus intravenous iron sucrose in treatment of iron deficiency anaemia of pregnancy. Int J Reprod Contracept Obstet Gynecol. 2020;9(9):3852–3857. doi:10.18203/2320‑1770.ijrcog20203495
15. Prajapati SM, Patel MK. A study of efficacy of oral iron and intravenous iron sucrose in the treatment of moderate anemia in pregnancy. Int J Reprod Contracept Obstet Gynecol. 2019;8(6):2221–2226. doi:10.18203/2320‑1770.ijrcog20192163